| Summary: | 碩士 === 國立中興大學 === 獸醫學系暨研究所 === 100 === The clinical outcome for patients with unresectable or metastatic canine and feline sarcomas is poor, so it is merited to study novel or targeted therapy of canine and feline soft tissue and bone sarcomas. Recently, several studies indicated activation of EGFR-Akt and EGFR-Stat3 signaling pathways play roles in cancer development and progression. The aim of this study is to investigate the expressions and activations of EGFR-Akt and EGFR-Stat3 signaling pathway proteins in various canine sarcomas and feline injection site sarcomas (FISS). The expression and location of endogenous and phosphorylated forms of EGFR, Akt and Stat3 in 101 canine sarcomas, 12 FISS, 37 benign tumors and 22 normal tissues were evaluated by immunohistochemical stain. Results showed that activations of EGFR-Akt and EGFR-Stat3 signal pathways in fibrosarcomas, liposarcomas, hemangiosarcomas, and bone sarcomas were significantly higher than that in benign tumors, including fibromas, lipomas and hemangiomas, and normal tissues, including fibrocollagenous tissues, adipose tissues, capillaries and bone tissues (P ≤ 0.049). 100% FISS showed positive expression of all marker proteins, and the proportion of positive expression of all proteins, except for EGFR, was significantly higher than that in normal tissues (P ≤ 0.029). Beside, overexpression of EGFR significantly associated with shorter overall survival times (P = 0.022), a significant association was shown between strong activation of p-Akt and metastasis (P = 0.004). The findings demonstrated that EGFR signal pathway played an important role in canine sarcomas and FISSs formation, and EGFR overexpression and p-Akt strong activation can be prognostic factors of dogs with sarcomas.
|
|---|
